
A US judge on Friday rejected former pharmaceutical executive Martin Shkreli’s objections to being banned for life from the drug industry and having to repay $64.6 million after jacking up the price of a lifesaving drug, reported Reuters.
Lawyers for Shkreli, 38, had argued that the ban was overbroad and violated his right to free speech under the US Constitution’s First Amendment by barring him from publicly discussing the drug industry, even on a blog.
In imposing a permanent injunction, US District Judge Denise Cote said Shkreli’s antitrust violations cost him that right when he intended to “influence the management or business” of a pharmaceutical company.
The Manhattan-based judge also said that requiring Shkreli to sell his shares in Phoenixus AG, the parent of Vyera Pharmaceuticals Inc, did not violate his due process rights after he used his position as its largest shareholder to orchestrate the antitrust violations.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Elon Musk Leads $97.4 Billion Bid to Take Control of OpenAI
Feb 10, 2025 by
CPI
Nigerian Court Confirms Consumer Protection Commission’s Authority Over Telecom Sector
Feb 10, 2025 by
CPI
Microsoft Under French Antitrust Investigation Over Bing Practices
Feb 10, 2025 by
CPI
Hausfeld Grows Antitrust Litigation Team
Feb 10, 2025 by
CPI
Microsoft Seeks to Ease EU Antitrust Concerns With Office Pricing Adjustment
Feb 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon